SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

KURA

Kura Oncology, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The early revenue generation and rapid payer adoption of KOMZIFTI suggest strong commercial viability. With multiple clinical data readouts expected in 2026 and a well-funded runway into 2028, traders should monitor upcoming data from KOMET-007 (1H 2026) and the progression of Phase 3 frontline trials as key value inflection points.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.51
T+0 close · Mar 5, 2026 · via day close
Latest settled
+6.17%
T+60 · $9.04
Vs SPY
−5.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $8.51entry
  2. T+1 · 9mo ago +5.29%α +6.60% · $8.96
  3. T+5 · 8mo ago +3.88%α +6.12% · $8.84
  4. T+20 · 8mo ago +1.18%α +4.96% · $8.61
  5. T+60 · 6mo ago +6.17%α −5.13% · $9.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology reported Q4 and full-year 2025 financial results, highlighted by $2.1 million in net product revenue from the initial five weeks of KOMZIFTI™ (ziftomenib) commercial sales following its November 13 FDA approval for R/R NPM1-mutated AML. The company emphasized strong early commercial momentum, rapid payer coverage, and a robust cash position of $667.2 million, which, combined with $180 million in anticipated collaboration payments, is expected to fund operations into Q4 2027 and advance ziftomenib to Phase 3 topline data in frontline AML by 2028.

Key Financial Metrics

Revenue
$2.1M
EPS
$-1.92
Deal Value
$135.0M

Key Facts

  • Generated $2.1 million in net product revenue from KOMZIFTI in first five weeks post-FDA approval (Nov 13–Dec 31, 2025)
  • Received $135 million milestone payment from Kyowa Kirin upon product delivery within five days of approval
  • Cash, cash equivalents, and short-term investments totaled $667.2 million as of December 31, 2025
  • Anticipated $180 million in future collaboration payments from Kyowa Kirin to support development through Phase 3 AML data
  • Net loss widened to $81.0 million in Q4 2025 vs. $19.2 million in Q4 2024 due to increased R&D and SG&A expenses tied to commercialization
  • Initiated pivotal Phase 3 KOMET-017 trials in frontline AML, triggering two $30 million milestone payments from Kyowa Kirin

Financial Impact

$2.1 million in net product revenue in first partial quarter; $15.2 million collaboration revenue in Q4; total cash resources (~$847M with expected milestones) sufficient to fund through key 2028 Phase 3 readout

revenuecashR&D expenseSG&A expensenet loss

Risk Factors

  • Differentiation syndrome observed in 26% of patients, including fatal cases, which may limit use or require risk mitigation
  • Widening net loss ($81M in Q4) driven by rising R&D and commercialization costs
  • Future collaboration payments from Kyowa Kirin are contingent on milestones and not guaranteed

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249967

Track record

29 reports on KURA

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026